Erin Becker

European Patent Attorney

Ph.D., B.Sc., Biology

Dr. Becker is authorized to represent clients before the European Patent Office. She has been active in the field of intellectual property since 2009. She complements our firm as a European Patent Attorney in biotechnology and pharmaceuticals department.

+ 49 89 210 296 0
erin.becker@df-mp.com
 

Dr. Becker is authorized to represent clients before the European Patent Office. She has been active in the field of intellectual property since 2009. She complements our firm as a European Patent Attorney in biotechnology and pharmaceuticals department.

practice areas.

Dr. Becker’s scientific background lies in immunology, hematology, cell biology and genetics. She is involved in patent drafting and prosecution concerning European patents. She is also active in opposition and appeal matters before the European Patent Office.

 

admissions.

  • European Patent Attorney

references and activities.

  • Author of scientific publications

curriculum vitae.

Since 2015
Since 2015

European Patent Attorney at df-mp

2012-2014
2012-2014

European Patent Consultant for df-mp in West Hartford, Connecticut, USA

2009-2012
2009-2012

European Patent Attorney Trainee at df-mp

2006-2009
2006-2009

Postdoctoral Fellow at the Institute for Stem Cell Research, Helmholtz Zentrum München in Munich (behavioural analysis of single blood stem cells in their niche) Funded by an Alexander von Humboldt Post-doctoral Research Fellowship and a Marie Curie Post-doctorate Fellowship from the European UnionAlexander von Humboldt-Forschungsstipendium und Marie-Curie-Fellowship der Europäischen Union

2000-2005
2000-2005

Ph.D. in Genetics from the University of British Columbia, Canada (doctoral thesis on the function of the sialomucins CD34 and CD43 on mast cells and mast cell progenitors)

1996-2000
1996-2000

B.Sc. in Cell Biology & Genetics from the University of British Columbia, Canada

publications.

  • Kokkaliaris KD, Drew E, Endele M, Loeffler D, Hoppe PS, Hilsenbeck O, Schauberger B, Hinzen C, Skylaki S, Theodorou M, Kieslinger M, Lemischka I, Moore K, Schroeder T. “Identification of factors promoting ex vivo maintenance of mouse hematopoietic stem cells by long-term single-cell quantification.” Blood. 2016 Sep 1;128(9):1181-92.
  • Eilken HM, Rieger MA, Hoppe PS, Hermann AC, Smejkal BM, Drew EC, Thum M, Ninkovic J, Beckervordersandforth RM and Schroeder T. “Continuous long-term detection of live cell surface markers by ‘in culture’ antibody staining.” Protocol Exchange. 2011 Jan 28; doi:10.1038/protex.2011.205.
  • Drew E and Schroeder TT. “The Big Brother of Blood: The Need for Constant Video Surveillance of Individual Cells.” New Cell Differentiation Research Topics, Nova Science Publishers Inc., 2007, 229-246.
  • Camargo FD, Chambers SM, Drew E, McNagny KM, Goodell MA. “Hematopoietic stem cells do not engraft with absolute efficiencies.” Blood. 2006 Jan 15;107(2):501-7.
  • Drew E, Huettner CS, Tenen DG, McNagny KM.“CD34 expression by mast cells: of mice and men.” Blood. 2005 Sep 1;106(5):1885-7.
  • Doyonnas R, Nielsen JS, Chelliah S, Drew E, Hara T, Miyajima A, McNagny KM. “Podocalyxin is a CD34-related marker of murine hematopoietic stem cells and embryonic erythroid cells.” Blood.2005 Jun 1;105(11):4170-8.
  • Drew E, Merzaban JS, Seo W, Ziltener HJ, McNagny KM.“CD34 and CD43 inhibit mast cell adhesion and are required for optimal mast cell reconstitution.” Immunity. 2005 Jan;22(1):43-57.
  • Drew E, Merkens H, Chelliah S, Doyonnas R, McNagny KM. “CD34 is a specific marker of mature murine mast cells.” Exp Hematol. 2002 Oct;30(10):1211.